Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201104 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL100170 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL101790 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL101587 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL100776 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL100937 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL101940 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL100035 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL1244658 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL201718 | 1.00 | LMNA (0.50) | LMNAALDH1A1TDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105518053-B | aliphatic polycarbonate compositions and methods | 诺沃梅尔公司 | 2017-07-21 | — | — | CN | claimed |
| US-9075281-B2 | Colored composition and image display structure | FUJIFILM CORPORATION (JP) | 2015-07-07 | — | — | US | claimed |
| US-20140293394-A1 | COLORED COMPOSITION AND IMAGE DISPLAY STRUCTURE | FUJIFILM CORPORATION (JP) | 2014-10-02 | — | — | US | claimed |
| CN-103998529-A | Coloring composition and image display structure | FUJIFILM CORP | 2014-08-20 | — | — | CN | claimed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023163463-A1 | RESIN COMPOSITION AND DISPLAY DEVICE COMPRISING SAME | 삼성디스플레이주식회사 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| US-11628145-B2 | Coloured keratolytic nail lacquer | OYSTERSHELL NV (BE) | 2023-04-18 | — | — | US | disclosed |
| US-11578031-B2 | Dissymmetric N,N-dialkylamides used particularly for separating uranium(VI) from plutonium(IV), synthesis thereof and uses of same | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÊNERGIES ALTERNATIVES (FR) | 2023-02-14 | — | — | US | disclosed |
| CN-110312702-B | Asymmetric N, N-dialkylamides, in particular for separating uranium (VI) and plutonium (IV), their synthesis and use | 原子能和替代能源委员会 | 2022-10-14 | — | — | CN | disclosed |
| EP-3366277-B1 | PEELABLE NAIL LACQUER | OYSTERSHELL NV (BE) | 2021-11-17 | — | — | EP | disclosed |
| US-20210332002-A1 | DISSYMMETRIC N,N-DIALKYLAMIDES USED PARTICULARLY FOR SEPARATING URANIUM(VI) FROM PLUTONIUM(IV), SYNTHESIS THEREOF AND USES OF SAME | ORANO CYCLE (FR) | 2021-10-28 | — | — | US | disclosed |
| US-5968919-A | CONTAINING PENETRATION ENHANCER OF (HYDROCARBYL-SUBSTITUTED) 1,3-DIOXOLANE, 1,3-DIOXANE OR ACETAL | MACROCHEM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5942545-A | Composition and method for treating penile erectile dysfunction | MACROCHEM CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999039680-A1 | ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME | MACROCHEM CORPORATION (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999020257-A1 | HORMONE REPLACEMENT THERAPY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MACROCHEM CORPORATION (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999009954-A1 | NON-STEROIDAL ANTIINFLAMMATORY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MACROCHEM CORPORATION (US) | 1999-03-04 | — | — | WO | disclosed |
| US-4325973-A | Hydroxyalkyl amides as fungicides to eumycotina in phanerogamia plant life | GAF CORPORATION (US) | 1982-04-20 | — | — | US | disclosed |
| US-4254214-A | BLACK, REDUCTION OF COPPER SALT OR COMPLEX TO COPPER | FUJI PHOTO FILM CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| US-4195096-A | NONTOXIC, BIODEGRADABLE | GAF CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578031-B2 | Dissymmetric N,N-dialkylamides used particularly for separating uranium(VI) from plutonium(IV), synthesis thereof and uses of same | NOS2, NOS1, NOS3 | LMNA 107/4885ALDH1A1 1859/4885TDP1 841/4885 |
| US-20210332002-A1 | DISSYMMETRIC N,N-DIALKYLAMIDES USED PARTICULARLY FOR SEPARATING URANIUM(VI) FROM PLUTONIUM(IV), SYNTHESIS THEREOF AND USES OF SAME | NOS2, NOS1, NOS3 | LMNA 107/4885ALDH1A1 1859/4885TDP1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.